Advertisement
U.S. markets open in 7 hours 12 minutes

Geron Corp (GON.DU)

Dusseldorf - Dusseldorf Delayed Price. Currency in EUR
1.9410+0.0450 (+2.37%)
As of 07:30PM CET. Market open.
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.8960
Open1.8630
Bid1.8810 x 0
Ask1.9390 x 0
Day's Range1.8630 - 1.9410
52 Week Range1.5660 - 3.4320
Volume500
Avg. Volume16
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateFeb 28, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for GON.DU

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Business Wire

      Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      FOSTER CITY, Calif., February 22, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 397,010 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.

    • Business Wire

      Geron to Announce Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

      FOSTER CITY, Calif., February 14, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2023 financial results and business highlights before the market opens on Wednesday, February 28, 2024 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as business highlights at 8:00 a.

    • Business Wire

      Geron to Participate in the B. Riley Securities Virtual Oncology Conference

      FOSTER CITY, Calif., January 12, 2024--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer, is scheduled to participate in a fireside chat at the B. Riley Securities Virtual Oncology Conference on Thursday, January 18th, 2024, at 10:30am ET.